TY - JOUR
T1 - Axillary arterial bleeding with administration of bevacizumab plus paditaxel in a patient with recurrent breast cancer-A case report
AU - Tsuruda, Yusuke
AU - Masuda, Takaaki
AU - Hayashi, Naoki
AU - Noda, Miwa
AU - Otsu, Hajime
AU - Kuroda, Yosuke
AU - Eguchi, Hidetoshi
AU - Tanaka, Fumiaki
AU - Natsugoe, Shoji
AU - Mimori, Koshi
N1 - Publisher Copyright:
© 2020 Japanese Journal of Cancer and Chemotherapy Publishers Inc.. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/1
Y1 - 2020/1
N2 - We report a case of axillary arterial bleeding after administration of bevacizumab plus paditaxel in a patient with recurrent breast cancer. A 50-year-old woman with invasive ductal carcinoma of the left breast underwent mastectomy and sentinel node biopsy. She was administered 4 courses of docetaxel and cyclophosphamide as adjuvant chemotherapy. Twenty-eight months after the surgery, she developed axillary lymph node recurrence with pain and upper-limb paralysis. Initially, radiation therapy was performed in the axilla combined with the oral administration of TS-1. However, the response was inadequate. Subsequently, bevacizumab plus paditaxel was administered. After 2 courses, we observed remarkable shrinkage of the axillary tumor. However, she experienced massive bleeding from the axillary artery. As the bleeding recurred, we ligated the axillary artery. Caution is required while administrating bevacizumab in cases of tumors located close to the major blood vessels.
AB - We report a case of axillary arterial bleeding after administration of bevacizumab plus paditaxel in a patient with recurrent breast cancer. A 50-year-old woman with invasive ductal carcinoma of the left breast underwent mastectomy and sentinel node biopsy. She was administered 4 courses of docetaxel and cyclophosphamide as adjuvant chemotherapy. Twenty-eight months after the surgery, she developed axillary lymph node recurrence with pain and upper-limb paralysis. Initially, radiation therapy was performed in the axilla combined with the oral administration of TS-1. However, the response was inadequate. Subsequently, bevacizumab plus paditaxel was administered. After 2 courses, we observed remarkable shrinkage of the axillary tumor. However, she experienced massive bleeding from the axillary artery. As the bleeding recurred, we ligated the axillary artery. Caution is required while administrating bevacizumab in cases of tumors located close to the major blood vessels.
UR - http://www.scopus.com/inward/record.url?scp=85084390904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084390904&partnerID=8YFLogxK
M3 - Article
C2 - 32381877
AN - SCOPUS:85084390904
VL - 47
SP - 117
EP - 119
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 1
ER -